» Articles » PMID: 38909024

KLHL14 is a Tumor Suppressor Downregulated in Undifferentiated Thyroid Cancer

Overview
Date 2024 Jun 22
PMID 38909024
Authors
Affiliations
Soon will be listed here.
Abstract

KLHL14 is a substrate-binding subunit of Cullin-RING ligase 3 ubiquitin ligase complex, highly enriched in thyroid since early embryonic development, together with its antisense RNA KLHL14-AS. We have previously demonstrated that Klhl14-AS is a competing endogenous RNA regulating several differentiation and survival factors in thyroid cancer, acting as tumor suppressor. Recently, also KLHL14 has been shown to function as tumor suppressor in diffuse large B-cell lymphoma and in malignant mesothelioma. Here we show that KLHL14 expression is strongly reduced in anaplastic thyroid cancer, the less differentiated and most aggressive type of thyroid neoplasia. Such reduction is reproduced in different in vivo and in vitro models of thyroid cancer, being invariably associated with loss of differentiation. When Klhl14 expression is rescued in thyroid transformed cells, it reduces the cell proliferation rate and increase the number of apoptotic cells. On the other side, Klhl14 loss of function in normal thyroid cells affects the expression of several regulatory as well as functional thyroid markers. All these findings suggest that KLHL14 could be considered as a novel tumor suppressor in thyroid cancer, by also revealing its physiological role in the maintenance of a fully differentiated and functional thyroid phenotype.

Citing Articles

KLHL14 and E-Cadherin Nuclear Co-Expression as Predicting Factor of Nonfunctioning PitNET Invasiveness: Preliminary Study.

Berardinelli J, Russo V, Canciello A, Di Giacinto O, Mauro A, Nardinocchi D J Clin Med. 2024; 13(15).

PMID: 39124679 PMC: 11312959. DOI: 10.3390/jcm13154409.

References
1.
Chakravarty D, Santos E, Ryder M, Knauf J, Liao X, West B . Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011; 121(12):4700-11. PMC: 3225989. DOI: 10.1172/JCI46382. View

2.
Fagin J, Krishnamoorthy G, Landa I . Pathogenesis of cancers derived from thyroid follicular cells. Nat Rev Cancer. 2023; 23(9):631-650. PMC: 10763075. DOI: 10.1038/s41568-023-00598-y. View

3.
Kondo T, Ezzat S, Asa S . Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006; 6(4):292-306. DOI: 10.1038/nrc1836. View

4.
Mulcahy R, Rosenkrans Jr W, Penney D, Cooper R . The growth and morphology of FRTL-5 thyroid epithelial cells grown as multicellular spheroids in vitro. In Vitro Cell Dev Biol. 1985; 21(9):513-20. DOI: 10.1007/BF02620844. View

5.
De Vita G, Bauer L, Correa da Costa V, De Felice M, Baratta M, De Menna M . Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. Mol Endocrinol. 2004; 19(1):76-89. DOI: 10.1210/me.2004-0172. View